Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Oncolytics Biotech Inc. has filed a Follow-on Equity Offerin

<< Previous

Bullboard Posts

Next >>

Comment by Angler101on Aug 04, 2024 7:08pm

85 Views

Post# 36164058

RE:RE:RE:RE:Oncolytics Biotech Inc. has filed a Follow-on Equity Offerin

It's good to see we at least agee on something!...still can't understand why you'e you're cheering for another 4 years of appallingly bad foreign policy, 50% higher gas prices, (and very likely to go higher) and a WIDE OPEN southern border to let in another 10 million unvetted strangers!....it boggles the mind why anyone could think those are winning policies!

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023